These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1775676)

  • 1. Effect of controlled-release salbutamol in predominantly non-reversible chronic airflow obstruction.
    Mohammed AF; Anderson K; Matusiewicz SP; Boyd G; Greening AP; Thomson NC
    Respir Med; 1991 Nov; 85(6):495-500. PubMed ID: 1775676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction.
    Taylor DR; Buick B; Kinney C; Lowry RC; McDevitt DG
    Am Rev Respir Dis; 1985 May; 131(5):747-51. PubMed ID: 4003919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and pharmacological study of a novel controlled release preparation of salbutamol.
    Milroy R; Carter R; Carlyle D; Boyd G
    Br J Clin Pharmacol; 1990 May; 29(5):578-80. PubMed ID: 2190630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose and steady-state effects of controlled-release salbutamol on drug level and airflow obstruction in patients with asthma.
    Tan WC; Chan TB; Ang SM
    Singapore Med J; 1992 Aug; 33(4):371-4. PubMed ID: 1411667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.
    Jarvis B; Markham A
    Drugs Aging; 2001; 18(6):441-72. PubMed ID: 11419918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-response study of inhaled salbutamol powder in chronic airflow obstruction.
    Corris PA; Neville E; Nariman S; Gibson GJ
    Thorax; 1983 Apr; 38(4):292-6. PubMed ID: 6867983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
    Appleton S; Smith B; Veale A; Bara A
    Cochrane Database Syst Rev; 2000; (2):CD001104. PubMed ID: 10796594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study.
    Ulrik CS
    Thorax; 1995 Jul; 50(7):750-4. PubMed ID: 7570409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy and systemic effects of 4 mg and 8 mg formulations of salbutamol controlled release in patients with asthma.
    Lipworth BJ; Clark RA; Dhillon DP; Palmer JB; McDevitt DG
    Eur J Clin Pharmacol; 1990; 39(3):281-5. PubMed ID: 2257867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of corticosteroids on bronchodilator action in chronic obstructive lung disease.
    Wempe JB; Postma DS; Breederveld N; Kort E; van der Mark TW; Koëter GH
    Thorax; 1992 Aug; 47(8):616-21. PubMed ID: 1412119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of controlled-release salbutamol on sleep and nocturnal oxygenation in patients with asthma and chronic obstructive pulmonary disease.
    Veale D; Cooper BG; Griffiths CJ; Corris PA; Gibson GJ
    Respir Med; 1994 Feb; 88(2):121-4. PubMed ID: 8146409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of a controlled-release tablet of salbutamol given twice daily with a standard tablet given four times daily in the management of chronic obstructive lung disease.
    Maesen FP; Smeets JJ
    Eur J Clin Pharmacol; 1986; 31(4):431-6. PubMed ID: 3816923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simplifying the assessment of patients with chronic airflow limitation for home nebulizer therapy.
    Goldman JM; Teale C; Muers MF
    Respir Med; 1992 Jan; 86(1):33-8. PubMed ID: 1533047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of reversible chronic airways obstruction with doxofylline compared with slow-release theophylline: a double-blind, randomized, multicentre trial.
    Melillo G; Balzano G; Jodice F; De Felice A; Campisi V; Capone M; Di Filippo A; Foddai G; Franzone JS; Grossi E
    Int J Clin Pharmacol Res; 1989; 9(6):397-405. PubMed ID: 2699466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease--a 3-month comparison of the efficacy and safety of twice-daily salmeterol (100 micrograms) with salmeterol (50 micrograms).
    Palmer JB; Stuart AM; Shepherd GL; Viskum K
    Respir Med; 1992 Sep; 86(5):409-17. PubMed ID: 1361068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life.
    Guyatt GH; Townsend M; Pugsley SO; Keller JL; Short HD; Taylor DW; Newhouse MT
    Am Rev Respir Dis; 1987 May; 135(5):1069-74. PubMed ID: 3579005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The additive effect of theophylline on a high-dose combination of inhaled salbutamol and ipratropium bromide in stable COPD.
    Nishimura K; Koyama H; Ikeda A; Sugiura N; Kawakatsu K; Izumi T
    Chest; 1995 Mar; 107(3):718-23. PubMed ID: 7874943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Formoterol as inhalation powder in the treatment of patients with reversible obstructive lung diseases. A 3-month placebo-controlled comparison of the effects of formoterol and salbutamol, followed by a 12-month period with formoterol alone].
    Steffensen IE; Faurschou P
    Ugeskr Laeger; 1996 Dec; 158(49):7092-6. PubMed ID: 8999618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained release oral aminophylline in patients with airflow obstruction.
    Greening AP; Baillie E; Gribbin HR; Pride NB
    Thorax; 1981 Apr; 36(4):303-7. PubMed ID: 7025336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinico-pharmacologic study of a new sustained-release oral salbutamol preparation in patients with obstructive airway disease].
    Bauer K; Lorenz PR; Seibel K; Neiss A; Eandi M; Kaik G
    Arzneimittelforschung; 1989 Jul; 39(7):801-4. PubMed ID: 2675854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.